JOURNAL OF PRACTICAL HEPATOLOGY ›› 2015, Vol. 18 ›› Issue (2): 205-208.doi: 10.3969/j.issn.1672-5069.2015.02.029
• Orignal Article • Previous Articles Next Articles
Chen Jianhong, Liu Yan, Li Jin, Xu Dongping
Received:
2014-08-10
Online:
2015-03-10
Published:
2016-02-19
Chen Jianhong, Liu Yan, Li Jin, Xu Dongping. Occult hepatitis B virus infection: Present and future[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2015, 18(2): 205-208.
[1] Hoofnagle JH,minary results of HBV DNA testing of Polish haemophillia patients-lack of occult HBV infection. Haemophillia,2006,12(4):380-383. [5] Rinonce HT,Yano Y,Utsumi T,et al. Hepatitis B and C virus infection among hemodialysis patients in Yogyakarta,Indomesia:Prevalence and molecular evidence for nosocomial transmission.J Med Virol,2013,85(8):1348-1361. [6] Wong DK,Huang FY,Lai CL,et al. Occult hepatitis B infection and HBV replicative activity in patients with cryptogenic cause of hepatocellular carcinoma. Hepatology,2011,54(3):829-836. [7] Minuk GY,Sun DF,Uhanova J,et al. Occult hepatitis B virus infection in a North American community-based population. J Hepatol,2005,42(4):480-485. [8] Ireland JH,OHeland JB,Basuni AA,et al. Ractivity of 13 in vitro expressed hepatitis B surface antigen variants in 7 commercial diagnostic assays. Hepatology,2000,31(5):1176-1182. [9] Bes M,Vargas V,Piron M,et al. T cell responses and viral variability in blood donation candidates with occult hepatitis B infection. J Hepatol,2012,56(4):765-774. [10] Feitelson MA,Lee J. Hepatitis B virus integration, fragile sites,and hepatocarcinogenesis. Cancer Lett,2007,252(2):157-170. [11] Huang CH,Yuan Q,Chen PJ, et al.Influence of mutations in hepatitis B virus surface protein on viral antigenicity and phenotype in occult HBV strains from blood donors. J Hepatol,2012,57(4):720-729. [12] Biswas S,Candotti D,Allain JP. Specific amino acid substitutions in the S protein prevent its excretion in vitro and may contribute to occult hepatitis B virus infection. J Virol,2013,87(14):7882-7892. [13] Kim BK,Choi SH,Chung SH,et al. Pre-S mutations of hepatitis B virus affect genome replicationand expression of surface antigens. J Gastroenterol Hepatol,2014,29(4):843-850. [14] Yu DM, Li XH,Mom V,et al. N-glycosylation mutations within hepatitis B virus surface major hydrophilic region contribute mostly to immune escape. J Hepatol,2014,60(3):515-522. [15] Coffin CS,Pham TNQ,Mulrooney PM,et al. Persistence of isolated antibodies to woodchuck hepatitis virus core antigen is indicative of occult infection. Hepatology,2004,40(5):1053-1061. [16] Pollicino T,Raffa G,Costantino L,et al. Molecular and functional analysis of occult hepatitis B virus isolates from patients with hepatocellular carcinoma. Hepatology,2007,45(2):277-285. [17] Lucifora J,Durantel D,Testoni B,et al. Control of hepatitis B virus replication by innate response of HepaRG cells. Hepatology,2010,51(1):63-72. [18] Portela A,Esteller M. Epigenetic modifications and human disease. Nature Biotechnol,2010,28(10):1057-1068. [19] Vivekanandan P,Thomas D,Torbenson M. Methylation regulates hepatitis B viral protein expression.J Infect Dis,2009,199(9):1286-1291. [20] Pollicino T,Belloni L,Raffa G,et al. Hepatitis B virus replication is regulated by the acetylation status of hepatitis B virus cccDNA bound H3 and H4 histones. Gastroenterology,2006,130(3):823-837. [21] Conjeevaram HS,Lok AS. Occult hepatitis B virus infection:a hidden menace. Hepatology,2001,34(5):204-206. [22] Zhu W,Wu C,Deng W,et al. Inhibition of the HCV core protein on the immune response to HBV surface antigen and on HBV gene expression and replication in vivo. PLoS one,2012,7(9):e45146. [23] Bellecave P,Gouttenoire J,Gajer M,et al. Hepatitis B and C virus coinfection:a novel model system reveals the absence of direct viral interference. Hepatology,2009,50(1):46-55. [24] McClary H,Koch R,Chisari FV,et al. Inhibition of hepatitis B virus replication during schistosoma mansoni infection in transgenic mice. J Exp Med,2000,192(2):289-294. [25] Coppola N,Loquercio G,Tonziello G,et al. HBV transmission from an occult carrier with five mutations in the major hydrophilic region of HBsAg to an immunosuppressed plasma recipient. J Clin Virol,2013,58(1):315-317. [26] Raimondo G,Caccamo G,Filomia R,et al. Occult HBV infection. Semin Immunopathol,2013,35(1):39-52. [27] Pande C,Sarin SK,Patra S,et al. Hepatitis B vaccination with or without hepatitis B immunoglobulin at birth to babies born of HBsAg-positive mothers prevents overt HBV transmission but may not prevent occult HBV infection in babies:a randomized controlles trial. J Viral Hepat,2013,20(11):801-810. [28] Yeo W,Chan TC,Leung NW,et al. Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B,undergoing anticancer therapy with or without rituximab.J Clin Oncol,2009,27(4):605-611. [29] Squadrito G,Cacciola I,Alibrandi A,et al. Impact of occult hepatitis B virus infection on the outcome of chronic hepatitis C. J Hepatol,2013,59(4):696-700. [30] Ikeda K,Kobayashi M,Someya T,et al. Occult hepatitis B virus infection increases hepatocellular carcinogenesis by eight times in patients with non-B,non-C liver cirrhosis:A cohort study. J Viral Hepat,2009,16(6):437-443. [31] Chu CJ, Lee SD. Hepatitis B virus/hepatitis C virus coinfection:Epidemiology,clinicalfeatures,viralinteractionsand treatment. J Gastroenterol Hepatol,2008,23(4):512-520. [32] Stroffolini T,Almasio PL,Persico M,et al. Lack of correlation between serum anti-HBcore detectability and hepatocellular carcinoma in patients with HCV-related cirrhosis. Am J Gastroenterol,2008,103(8):1966-1972. [33] Boyault S,Rickman DS,de Reyniès A,et al. Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets. Hepatology,2007,45(1):42-52. [34] Huang X,Hollinger FB. Occult hepatitis B virus infection and hepatocellular carcinoma:a systematic review. J Viral Hepat,2014,21(3):153-162. [35] Chen CH,Changchien CS,Lee CM,et al. A study on sequence variations in pre-S/surface,X and enhancer II/core promoter /precore regions of occult hepatitis B virus in non-B,non-C hepatocellular carcinoma patients in Taiwan. Int J Cancer,2009,125(3):621-629. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||